Home  >  News
Eppen_CellXpert_Nov24
you can get e-magazine links on WhatsApp. Click here
News
  Takeda presents new data showing mezagitamab sustained effect on kidney function 18 months after treatment in primary IgA nephropathy,   November 10, 2025
  Gilead announces phase 3 ASCENT-07 study of Trodelvy versus chemotherapy to treat post-endocrine therapy in HR+/HER2-negative metastatic breast cancer fails to meet the primary endpoint of PFS,   November 10, 2025
  GSK presents data from its advancing liver pipeline at AASLD 2025,   November 10, 2025
  Sanofi & Regeneron’s Dupixent pivotal study meets all primary and secondary endpoints, reducing signs and symptoms of allergic fungal rhinosinusitis,   November 10, 2025
  WHO publishes new global research agenda to strengthen paediatric clinical trials,   November 07, 2025
  Radiant Biotherapeutics to present new data from lead oncology programme at SITC 2025 annual meeting,   November 06, 2025
  Lungpacer Medical announces first enrollments in STARI trial of next-generation neurostimulation therapy,   November 06, 2025
  Kamada begins patient enrolment in an investigator-initiated clinical trial of Cytogam to prevent cytomegalovirus in kidney transplantation,   November 06, 2025
  TScan Therapeutics reaches agreement with US FDA on pivotal study design for TSC-101 and announces strategic prioritization to advance TSC-101,   November 05, 2025
  Valneva reports positive results for phase 1 trial of second generation Zika vaccine candidate, VLA1601,   November 05, 2025
  Bristol Myers Squibb showcases new long-term and real-world data from cardiovascular portfolio at the AHA scientific sessions 2025,   November 05, 2025
  Roche’s phase III ALLEGORY study of Gazyva/Gazyvaro in adults with systemic lupus erythematosus meets its primary endpoint,   November 04, 2025
  Amgen to present new data from cardiovascular portfolio, including late-breaking results from phase 3 VESALIUS-CV trial of Repatha at AHA scientific sessions,   November 03, 2025
  Ascletis selects ASC36 for clinical development; plans to submit IND to US FDA in second quarter of 2026,   November 01, 2025
  Novotech maps global growth in radiopharmaceutical trials,   November 01, 2025
  PREVAIL phase III trial of gefurulimab meets its primary endpoint, demonstrating a statistically significant and clinically meaningful improvement from baseline in MG-ADL,   November 01, 2025
  DESTINY-Lung06 phase 3 trial of Enhertu initiated as first-line therapy in patients with HER2 overexpressing metastatic non-squamous NSCLC,   November 01, 2025
  REGENXBIO completes pivotal enrollment and initiates commercial production in Duchenne gene therapy programme,   October 31, 2025
  Novo Nordisk to present 11 abstracts at the 76th Annual American Association for Study of Liver Diseases congress,   October 31, 2025
  CREATE Medicines, Amsterdam University Medical Center begin in vivo CAR therapy trial in frontline setting for solid tumours,   October 31, 2025

 Back
 
Avians_2025
                                                         
Copyright © 2024 Saffron Media Pvt. Ltd | twitter
 
linkedin
 
 
linkedin
 
instagram